As you said @stocksa the extensive trial timeline blowout could be due to a combination of factors.
But I’m merely pointing out that Silvio, the CEO of MSB announced to the ASX back in April the anticipation of enrolment completion of the COVID ARDS trial would be July-Aug 2020. Now, somehow, it’s Jan-Mar 2021 with no apparent explanation that I recall.
Take it up with Silvio. Not me.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-667
-
- There are more pages in this discussion • 145 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
0.078(5.56%) |
Mkt cap ! $1.621B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $4.387M | 3.047M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 52990 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 54274 | 8 |
View Market Depth
| Last trade - 13.37pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |